|
|
|
|
|
Legal status
Patent expired
| (51) | INT.CL. | A61K 31/7076 | (2006.01) |
| A61K 38/21 | (2006.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61P 25/28 | (2006.01) |
| (11) | Number of the document | 4070800 |
| (13) | Kind of document | T |
| (96) | European patent application number | 22166610.0 |
| Date of filing the European patent application | 2005-12-20 | |
| (97) | Date of publication of the European application | 2022-10-12 |
| (45) | Date of publication and mention of the grant of the patent | 2024-10-16 |
| (46) | Date of publication of the claims translation | 2025-01-10 |
| (30) | Number | Date | Country code |
| 638669 P | 2004-12-22 | US | |
| 04106909 | 2004-12-22 | EP |
| (72) |
De Luca, Giampiero , CH
Ythier, Arnaud , CH
Munafo, Alain , CH
Lopez-Bresnahan, Maria , CH
|
| (73) |
Merck Serono S.A. ,
Route de la Verrerie 6
Zone Industrielle, 1267 Coinsins,
CH
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Kladribino gydymo schema, skirta išsėtinei sklerozei gydyti |
| CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS |
| Payment date | Validity (years) | Amount | |
| 2024-12-03 | 347.00 EUR |